Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 1–2, pp 20–21 | Cite as

Schwerpunkt Amyloidose

Neuere pharmakologische Interventionen bei Leichtketten-Amyloidose

  • Ute HegenbartEmail author
  • Stefan Schönland
schwerpunkt
  • 138 Downloads

Bisher ist es noch nicht ausreichend gelungen, medikamentös die Bildung und Ablagerung von AL-Amyloidfibrillen zu verhindern bzw. diese abzubauen. Welche neueren Ansätze gibt es? Ein Überblick.

Literatur

  1. 1.
    Merlini G et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;25;4(1):38CrossRefGoogle Scholar
  2. 2.
    Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017;7(3):e546CrossRefGoogle Scholar
  3. 3.
    Richards DB et al. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med. 2015;373(12):1106–14CrossRefGoogle Scholar
  4. 4.
    Gertz MA et al. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J Clin Oncol. 2016;34(10):1097–103CrossRefGoogle Scholar
  5. 5.
    Ehrnhoefer DE et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008;15(6):558–66CrossRefGoogle Scholar
  6. 6.
    Hunstein W. Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood. 2007;110(6):2216CrossRefGoogle Scholar
  7. 7.
    aus dem Siepen F et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther. 2015;9:6319–25CrossRefGoogle Scholar
  8. 8.
    Hegenbart U et al. EGCG Treatment In Patients With Cardiac AL Amyloidosis: First Results Of A Randomized And Placebo-Controlled Clinical Trial of Germany. ISA. 2018;Abstr e278Google Scholar
  9. 9.
    Edwards CV, Gould J, Langer AL, et al. Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid. 2017;24(sup1):58–9CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Amyloidose-ZentrumUniversitätsklinikum HeidelbergHeidelbergDeutschland

Personalised recommendations